Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rapid Micro Biosystems, Inc. filings document the company's microbial quality-control automation business, governance matters and capital structure. Form 8-K reports furnish operating results, preliminary revenue updates, Regulation FD disclosures about the Growth Direct platform, and material agreements such as term-loan financing secured by company assets and related warrants for Class A common stock.
Proxy filings cover annual meeting procedures, stockholder voting matters, board governance and executive compensation disclosures. Other material-event reports address officer-transition and compensatory-arrangement disclosures, while recent cover pages identify the company as an emerging growth company for Exchange Act reporting purposes.
Rapid Micro Biosystems, Inc. director Richard S. Kollender reported equity awards under the company’s compensation program. He received 19,300 shares of Class A common stock as restricted stock units that were granted at no cash cost.
He was also granted stock options for 38,700 shares of Class A common stock at an exercise price of $2.07 per share, expiring on May 20, 2036. Both the RSUs and the options vest in full on the earlier of the first anniversary of the grant date or immediately before the next annual stockholders’ meeting, assuming continuous service. Following the RSU grant, he directly holds 130,318 shares of Class A common stock.
RAPID MICRO BIOSYSTEMS, INC. director Dafni Bika received new equity awards. She was granted 19,300 shares of Class A Common Stock as restricted stock units and 38,700 stock options with a $2.07 exercise price. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or immediately before the next annual stockholders meeting, contingent on continuous service.
Rapid Micro Biosystems disclosed that Bain Capital Life Sciences–affiliated entity BCLS I Investco, LP bought a package of warrants in an underwritten public offering. BCLS I Investco acquired a Pre-Funded Warrant, an accompanying Series A Warrant, and an accompanying Series B Warrant, each giving the right to purchase 1,463,000 shares of Class A Common Stock. The combined unit price for each pre-funded warrant plus Series A and Series B Warrants was $1.945. The pre-funded warrant has a $0.01 exercise price and does not expire, while the Series A and Series B Warrants have exercise prices of $1.955 and $2.34, respectively, and stated future exercise periods. All three warrants are subject to a 9.99% beneficial ownership limit. The Bain Capital Life Sciences entities also report indirect ownership of 8,434,560 shares of Class A Common Stock following the transaction.
Rapid Micro Biosystems, Inc. entered an underwriting agreement for an underwritten offering of 3,581,000 Class A common shares with accompanying Series A and Series B common stock warrants, plus up to 1,463,000 pre-funded warrants with accompanying warrants. The company estimates net proceeds of about $8.9 million, to be used for working capital and general corporate purposes.
The warrants have exercise prices of $1.955 and $2.340 per share, with Series A warrants expiring one year after becoming exercisable and Series B warrants expiring five years after becoming exercisable. A concurrent registered direct offering with directors and officers covers 71,607 shares with matching warrant terms for approximately $140,000 in gross proceeds and is contingent on closing of the main offering.
Rapid Micro Biosystems, Inc. is offering 71,607 shares of Class A common stock, each sold together with a Series A warrant (exercise price $1.955) and a Series B warrant (exercise price $2.34), at a combined price of $1.955 per share, subject to consummation of, the Underwritten Offering. The company expects net proceeds of approximately $140,000, with the offering expected to close on or about May 20, 2026. Certain directors and officers have agreed to purchase an aggregate of approximately $140,000 in this offering. The prospectus supplement discloses exercise windows, expiration terms for the Series A and Series B warrants, and pro forma shares outstanding of 44,920,118 Class A shares assuming no warrant exercises, based on March 31, 2026 balances.
Rapid Micro Biosystems is offering 3,581,000 shares of Class A common stock together with accompanying Series A and Series B warrants and pre-funded warrants to certain investors under a prospectus supplement dated May 18, 2026. The offering also includes pre-funded warrants to purchase 1,463,000 shares and accompanying warrants.
The combined public offering price is $1.955 per share (and $1.945 per pre-funded warrant), with the company expecting to receive approximately $8.9 million in net proceeds after underwriting discounts and estimated offering expenses. The prospectus supplement states Series A warrants (exercise price $1.955) are exercisable six months after issuance and expire one year after issuance; Series B warrants (exercise price $2.34) are exercisable six months after issuance and expire five years after issuance.
Rapid Micro Biosystems, Inc. Schedule 13G/A Amendment No. 2 discloses that certain Longitude entities and two affiliated individuals report shared beneficial ownership of 3,529,245 shares of Class A common stock, representing 8.6% of the class. The filing cites March 31, 2026 as the share count reference, with 41,267,511 shares outstanding reported in the issuer's proxy statement.
The reporting persons named include Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., and individuals Patrick G. Enright and Juliet Tammenoms Bakker. The filing states these shares are held of record by LVPII and that LCPII, as general partner, and the two managing members may be deemed to share voting and dispositive power.
Rapid Micro Biosystems, Inc. reported Q1 2026 revenue of $8.0 million, up modestly from $7.2 million a year earlier, driven by higher product revenue. Service revenue declined slightly.
The company posted a net loss of $14.3 million (loss of $0.31 per share), widening from a $11.3 million loss in Q1 2025, as operating expenses rose to $14.2 million, led by higher general and administrative and sales and marketing costs. Operating cash outflow was $15.1 million, and total stockholders’ equity fell to $20.4 million from $33.2 million at year-end 2025.
Cash, cash equivalents and short-term investments totaled about $22.9 million as of March 31, 2026, alongside a $20.0 million term loan under a facility of up to $45.0 million. Management believes existing cash, investments and expected borrowing capacity will fund operations and capital needs for at least twelve months.
Rapid Micro Biosystems reported first quarter 2026 revenue of $8.0 million, up 11.1% from $7.2 million a year earlier, driven by 36% growth in product revenue to $5.6 million and 27.7% growth in recurring revenue to $5.1 million. The company placed six new Growth Direct systems versus three in the prior-year quarter, but service revenue declined 21.9% to $2.4 million due to lower validation activity. Gross margin was 4.6% on cost of revenue of $7.6 million, while operating expenses rose 17.9% to $14.2 million, leading to a wider net loss of $14.3 million, or $0.31 per share, compared with a $11.3 million loss, or $0.26 per share, in 2025. Cash, cash equivalents, short-term investments, and restricted cash fell to $23.2 million at March 31, 2026, from $38.6 million at year-end 2025. The company reaffirmed full-year 2026 guidance for total revenue of $37.0 million to $41.0 million, gross margin of about 20%, and 30 to 38 Growth Direct system placements.